Lupus & antiphospholipid syndrome
Molecular characterisation of lupus low disease activity state (Lupus LDA State (LLDAS)) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort
Authors' conclusion
We demonstrated for the first time molecular signalling pathways distinguishing LLDAS/remission from active SLE. LLDAS/remission was associated with reversal of biological processes related to SLE pathogenesis and specific clinical manifestations.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients from the PRECISESADS project
- Participants
- 321 patients
- Exposure
- LLDAS vs non-LLDAS; DORIS remission vs non-remission; LLDAS exclusive of remission
- Outcome
- Differentially expressed pathways (DEPs)
Methodological detailswhole-blood transcriptome-based pathway analysis, pan-European cohort
- Whole-blood transcriptome-based pathway analysis
- pan-European cohort
Main finding
As reported in the abstract
Differentially expressed pathways
- Patients in LLDAS
- 40.8%
- Patients in DORIS remission
- 17.4%
- Patients in LLDAS after exclusion of patients in remission
- 28.3%
- Pathways differing significantly, LLDAS vs non-LLDAS (q<0.05, dr≥0.36)
- 604
- Pathways differing significantly, DORIS remitters vs non-remitters (q<0.05, dr≥0.36)
- 288
Observational data: associations, not effects.
Original publication
Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort. Ann Rheum Dis. Published 12 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →